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Abstract
Objective To measure the association between use of proton pump
inhibitors and a range of harmful outcomes in patients using clopidogrel
and aspirin.
Design Observational cohort study and self controlled case series.
Setting United Kingdom General Practice Research Database with
linked data from theMyocardial Ischaemia National Audit Project (MINAP)
and the Office for National Statistics (the cardiovascular disease research
using linked bespoke studies and electronic records (CALIBER)
collaboration)
Population 24 471 patients receiving clopidogrel and aspirin.
Main outcome measures The primary outcome was death or incident
myocardial infarction. Secondary outcomes were death, incident
myocardial infarction, vascular death, and non-vascular death.
Comparisons were made between proton pump inhibitor use and
non-use.
Results Of the 24 471 patients prescribed clopidogrel and aspirin, 12
439 (50%) were also prescribed a proton pump inhibitor at some time
during the study. Death or incident myocardial infarction occurred in
1419 (11%) patients while they were receiving a proton pump inhibitor
compared with 1341 (8%) who were not receiving a proton pump inhibitor.
In multivariate analysis, the hazard ratio for the association between
proton pump inhibitor use and death or incident myocardial infarction
was 1.37 (95% confidence interval 1.27 to 1.48). Comparable results
were seen for secondary outcomes and with other 2C19 inhibitors and
with non-2C19 inhibitors. With the self controlled case series design to
remove the effect of differences between people, there was no
association between proton pump inhibitor use andmyocardial infarction,
with a rate ratio of 0.75 (0.55 to 1.01). Similarly, with the self controlled
case series there was no association with myocardial infarction for other
2C19 inhibitors/non-inhibitors.
Conclusion The lack of a specific association and the discrepancy
between findings of the analyses between and within people suggests
that the interaction between proton pump inhibitors and clopidogrel is
clinically unimportant.
Introduction
Clopidogrel is an antiplatelet drug often given with low dose
aspirin to patients with acute coronary syndrome or after
ischaemic stroke, with the aim of preventing further vascular
events. As clopidogrel and aspirin can both increase the risk of
bleeding, a proton pump inhibitor is often co-prescribed to help
reduce the risk of gastrointestinal bleeding. Over recent years
there has been much debate about whether some or all proton
pump inhibitors might reduce the effectiveness of clopidogrel
because of a drug interaction at the cytochrome P450 2C19
enzyme.1-12 Clopidogrel is a prodrug that is metabolised to an
active form, and this process is believed to occur primarily via
cytochrome P450 2C19. Proton pump inhibitors inhibit this
enzyme to varying degrees, and mechanistic studies show that
combined use of clopidogrel with omeprazole or lansoprazole
leads to a reduction in activity of clopidogrel as measured by
platelet aggregation and associated biomarkers. This suggests
that there is a potentially important pharmacokinetic interaction
between these drugs when used at therapeutic doses.13 14 The
question of clinical importance, however, is whether this
interaction has an impact on clinical outcomes. Evidence to date
has been conflicting; some studies have observed an increased
risk of vascular events in patients receiving clopidogrel and
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proton pump inhibitors,1 3-5 while others, including an
underpowered randomised trial, found no increased risk.2 6-12
Observational study designs might not always account for
confounding between people, and important differences between
patients who are and are not prescribed proton pump inhibitors
could account for the harmful effects observed.
We conducted two observational studies of differing designs to
investigate this possible drug interaction and compared the
findings. The first was a traditional cohort design, and the second
was a self controlled case series design. The self controlled case
series is a within person approach that eliminates fixed
confounding between people that can affect case-control or
cohort designs.15 The study was based on primary care
computerised clinical records from the United Kingdom based
General Practice Research Database, Office for National
Statistics mortality statistics, and the Myocardial Ischaemia
National Audit Project (MINAP). Newly established linkages
between these data sources provide a powerful research tool
ideal for examining questions of this nature.
Methods
The General Practice Research Database
The General Practice Research Database contains information
from over 11 million patients registered at over 600 general
practice surgeries in the UK.16 17 Continuous information is
recorded for each patient, including a record of each
consultation, any diagnoses made, all prescribed medicines, and
basic demographic data. The geographical distribution and size
of practices on the database is largely representative of the
population of England andWales, and the individuals registered
on the database are representative of the whole UK population
in terms of age and sex.18 The quality of data held in the database
is subject to rigorous checks and regular audits, and it has been
successfully used to conduct over 600 peer reviewed published
studies. The information obtained from the database is entirely
anonymised.
Myocardial Ischaemia National Audit Project
database
The Myocardial Ischaemia National Audit Project was
established in 1999 to track the quality of management of heart
attack in all 230 acute hospital trusts in England and Wales.19
Initially intended to capture information about ST elevation
myocardial infarctions only, the audit soon expanded to include
full information on all patients admitted with any suspected
acute coronary syndrome. The audit is managed by the National
Institute for Clinical Outcomes Research at University College
London in conjunction with the British Cardiac Society. For
this study, complete data on all incident myocardial infarctions
recorded in the project were available from 1 January 2003 to
31 July 2009.
As part of the CALIBER (cardiovascular disease research using
linked bespoke studies and electronic records) collaboration a
linkage has been established between the General Practice
Research Database and the Myocardial Ischaemia National
Audit Project and between the General Practice Research
Database and mortality records held by the Office for National
Statistics. All deaths identified in England andWales are notified
to the Office for National Statistics along with details of the
reported cause(s). Over 200 practices in the General Practice
Research Database are fully linked to both the Myocardial
Ischaemia National Audit Project and Office for National
Statistics mortality data. For all patients within these practices,
research data are available comprising the full General Practice
Research Database record for all patients and linked data for all
patients with a valid record within Myocardial Ischaemia
National Audit Project or Office for National Statistics mortality
statistics. The subset of linked General Practice Research
Database practices is broadly similar in profile to the full
complement of practices, suggesting generalisability is
maintained when the linked practices alone are used. The benefit
of using these linked data is that the researcher can access a rich
source of well characterised incident vascular and mortality
information as well as detailed primary care data, and the
linkages have already been shown to provide a useful
combination of high quality data for research.20 21
Study population
Patients were selected from all practices in the General Practice
Research Database with a linkage to Myocardial Ischaemia
National Audit Project and Office for National Statistics
mortality statistics. Patients had to be active within the General
Practice Research Database from 1 January 2003 onwards and
with at least 12 months between first registration and first
recorded prescription for clopidogrel. Patients also had to be
concurrently prescribed aspirin as recorded in the database
because aspirin can also be obtained without prescription. The
overall antiplatelet benefit being experienced by patients not
receiving prescribed aspirin is therefore unknown, and for this
reason such patients were ineligible.
Cohort analysis
Patients enter the cohort at the latest of 1 January 2003 or first
recorded prescription for clopidogrel in combination with
aspirin. Follow-up was censored at the earliest of stopping
treatment with clopidogrel, stopping treatment with aspirin,
occurrence of an outcome of interest, death, transfer out of the
practice, last data collection date for the practice, or 31 July
2009. Follow-up time was then classified according to whether
the patient was receiving a proton pump inhibitor as recorded
in the database, with time updated treatment status, allowing
patients to fluctuate between exposed and unexposed depending
on prescription patterns.
Treatment with aspirin was assumed to be continuous unless a
gastrointestinal bleed was recorded, from which time treatment
was assumed to be discontinued. For clopidogrel and proton
pump inhibitor exposure, where possible we calculated the
anticipated length of each prescription based on pack size and
dosing instructions. From all prescription records where this
information was available, we calculated the median length of
exposure from a single prescription. This median duration was
imputed for all individual prescriptions where duration was not
recorded. Courses of treatment were assumed to be continuous
when any apparent treatment break was less than 180 days, to
allow for partial non-compliance and situations where patients
might have built up treatment stocks or obtained drugs through
alternative sources. The primary exposure of interest was any
proton pump inhibitor. Given the varied capacity for 2C19
inhibition among individual proton pump inhibitors, however,
we also restricted exposure to strong inhibitors only
(omeprazole, lansoprazole, and esomeprazole). We examined
other drugs likely to be used over long periods by patients taking
clopidogrel as secondary exposures; other strong 2C19 inhibitors
included fluoxetine/paroxetine. Citalopram and ranitidine were
selected as a weak/non-2C19 inhibitors, with ranitidine used
for similar indications to proton pump inhibitors.22
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Outcomes
The primary outcome was a composite end point of all cause
mortality or incident myocardial infarction. Mortality was
determined fromOffice for National Statistics mortality records,
with incident myocardial infarction determined by Myocardial
Ischaemia National Audit Project records. Secondary end points
included incident myocardial infarction, all cause mortality, and
mortality attributed to vascular and non-vascular causes,
determined with cause of death information recorded by the
Office for National Statistics. Vascular causes of death were all
those assigned an ICD-10 (international classification of
diseases, 10th revision) code for “diseases of the circulatory
system” as the underlying cause.
Modelling strategy
Cox regression was carried out with Stata 11 (StataCorp, College
Station, TX, USA). Adjustments were made for age and sex,
with further adjustments considered for the following covariates
obtained from General Practice Research Database patient
records; smoking status, alcohol status, bodymass index (BMI)
categorised as <20, 20-25 or >25, diabetes, coronary heart
disease, peripheral vascular disease, ischaemic stroke, and
cancer. Patient status for each covariate was updated as relevant
at any change in exposure to a proton pump inhibitor. For the
small proportion of patients with missing status for smoking,
BMI, and alcohol intake, “missing” was included as an extra
category. Multiple imputation was considered, but these data
were not considered to be missing at random. Each covariate
was added to the model and retained on the basis of likelihood
ratio testing (P<0.05)
Self controlled case series analysis
The self controlled case series design method is derived from
rate modelling with a Poisson distribution and is comparable
with cohort methodology. It relies on comparisons within people
in a population of individuals who have both the outcome and
exposure of interest.15 Incidence rate ratios are derived,
comparing the rate of events during exposed periods of time
with the rate during all other observed time periods. A major
advantage of this design is that the potential confounding effect
of both recorded and unrecorded characteristics that vary
between individuals, but are fixed over time within individuals,
is removed. Age, which varies over time, is allowed for in the
analysis.
For each participant within the cohort we identified all of those
with at least one incident myocardial infarction during their
follow-up time as defined above. Periods of follow-up with no
exposure to a proton pump inhibitor are classified as baseline,
and follow-up time was further subdivided by age in single year
bands. For patients included in the self controlled case series
analysis, follow-up is not censored at the occurrence of the
event, as later exposed and unexposed periods of time need to
be included in the analysis. Figure 1 illustrates a typical
timeline⇓. As the self controlled case series design is well suited
to the study of acute and recurrent events, we used it to examine
the effect of proton pump inhibitor exposure on the occurrence
of myocardial infarction. Patients who had a myocardial
infarction but were never exposed to a proton pump inhibitor
were also included in the analysis to improve the adjustment
for age. Similarly, we also included those who were exposed to
a proton pump inhibitor for the entire observation period.
Other investigators using the self controlled case series design
have found that during a short period of time before the exposure
of interest the risk of the event of interest might be substantially
different from other baseline time periods.23 For this reason we
chose to separately analyse the two week period before use of
a proton pump inhibitor (see fig 1).
Model checking and sensitivity analyses
We investigated the proportional hazards assumption
underpinning Cox regression for the cohort analysis across age
categories. As a sensitivity analysis we examined exposure to
strong 2C19 inhibitors only (omeprazole, esomeprazole, and
lansoprazole). Because of missing data for smoking, BMI, and
alcohol consumption, we performed a complete case analysis
for comparison. For the self controlled case series analysis we
repeated all analyses without including a separate two week
lead in period and assumed all unexposed time was part of the
baseline risk period. The purpose of the lead in period in the
primary analysis is to allow for the possibility that the outcome
of interest could lead to a short term change (often a decrease)
in the chance of being prescribed the exposure of interest. This
would effectively reduce the incidence of events during the lead
in period, leading to a slight underestimate of the risk in the
baseline period. We also varied the period of time over which
continued drug exposure was assumed, alternatively allowing
periods of 90 or 60 days. We carried out an analysis restricted
to the first myocardial infarction during observation to check
the assumption of event independence. To account for possible
bias from event dependent observation censoring we performed
an analysis restricted to patients who were still alive three
months after their first myocardial infarction during the
observation period. Finally, to check whether the occurrence of
a myocardial infarction can lead to a subsequent change in the
risk of receiving a proton pump inhibitor, we restricted our
analysis to patients who had a first myocardial infarction before
the observation period began.
Results
We identified 24 471 patients receiving clopidogrel in
combination with aspirin and with at least 12 months’
registration in the General Practice Research Database before
their first prescription for clopidogrel. Table 1 shows the
background details for these patients⇓. Of these, 9111 (37%)
also received a proton pump inhibitor from the date of first
clopidogrel prescription. Those receiving proton pump inhibitors
were on average two years older than those who did not use a
proton pump inhibitor, with a median age of 71 years. Fifty
eight percent of users were men, compared with 65% of
non-users. Users of a proton pump inhibitor were also more
likely to have diabetes (34% v 29%), peripheral vascular disease
(12% v 11%), or cancer (15% v 13%) (table 1).
During follow-up, use of proton pump inhibitor was sporadic
in some patients and started later on in others. In total, 12 439
(50%) patients received a proton pump inhibitor at some point
during the study period. Conversely, 16 900 (69%) patients had
at least some follow-up time with no exposure to a proton pump
inhibitor.
Cohort analysis
Primary exposure (any proton pump inhibitor)
During follow-up (median 303 days), 2760 (11%) patients had
the primary outcome of all cause mortality or incident
myocardial infarction. In total 1419 (11%) events occurred
during periods of exposure to a proton pump inhibitor, while
1341 (8%) occurred during periods of no exposure (table 2⇓).
The crude hazard ratio for this association was 1.41 (95%
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confidence interval 1.31 to 1.52). After adjustment for age, sex,
BMI, smoking, alcohol, diabetes, peripheral vascular disease,
coronary heart disease, ischaemic stroke, and cancer the hazard
ratio was 1.37 (1.27 to 1.48; fig 2⇓).
In total, 2228 (9%) patients died during the study period; 1170
(9%) were exposed to a proton pump inhibitor at the time,
compared with 1058 (6%) not exposed to a proton pump
inhibitor. The crude hazard ratio for the association between
exposure and all cause mortality was 1.44 (1.32 to 1.56), with
a fully adjusted figure of 1.40 (1.29 to 1.52; fig 2). When we
considered mortality from underlying vascular causes only,
1226 patients died, with 612 (5%) exposed to a proton pump
inhibitor and 614 (4%) unexposed. The crude hazard ratio for
this association was 1.29 (1.15 to 1.44), with a fully adjusted
figure of 1.25 (1.12 to 1.40; fig 2). For mortality from underlying
causes other than vascular, 1002 patients died during follow-up;
558 (4%) while exposed to a proton pump inhibitor and 444
(3%) while unexposed. This association gave a crude hazard
ratio of 1.64 (1.44 to 1.85) and a fully adjusted figure of 1.61
(1.42 to 1.82; fig 2).
In the secondary analysis, in which we restricted the definition
of proton pump inhibitor to only those known to be strong
inhibitors of CYP450 2C19, the results obtained were similar
(table 3).
Secondary exposures (paroxetine/fluoxetine,
citalopram, ranitidine)
The non-2C19 inhibiting H2 receptor antagonist ranitidine was
used by 1561 patients at some point during follow-up, 105 (7%)
of whom had the primary outcome of all cause mortality or
incident myocardial infarction while receiving ranitidine (table
4⇓). This compared with 2655 (11%) patients with the primary
outcome during unexposed periods of follow-up, giving an
adjusted hazard ratio of 1.20 (0.99 to 1.46). The adjusted hazard
ratios for other outcomes were 1.25 (1.01 to 1.55) for all cause
mortality, 1.07 (0.72 to 1.59) for incident myocardial infarction,
1.06 (0.78 to 1.45) for vascular mortality, and 1.49 (1.11 to
1.99) for non-vascular mortality (see fig 2).
When we split follow-up time according to paroxetine or
fluoxetine exposure (strong 2C19 inhibiting antidepressants),
1143 patients were exposed to either antidepressant at some
point during follow-up (table 5⇓). In total, 109 patients had the
primary outcome during paroxetine/fluoxetine exposure time
(10%), compared with 2651 during unexposed time (11%). The
fully adjusted hazard ratio for this association was 1.42 (1.17
to 1.72). For other outcomes of interest the fully adjusted hazard
ratios were 1.49 (1.20 to 1.84) for all cause mortality, 1.13 (0.75
to 1.69) for incident myocardial infarction, 1.29 (0.95 to 1.75)
for vascular mortality, and 1.73 (1.29 to 2.31) for non-vascular
mortality (fig 2).
By contrast, the weak/non-2C19 inhibiting antidepressant
citalopram was used by 1930 patients during follow-up, and
207 (11%) of these had the primary outcome (table 6⇓). This
compared with 2553 (7%) in non-citalopram users and gave a
fully adjusted hazard ratio of 1.52 (1.32 to 1.76). For secondary
outcomes the fully adjusted hazard ratios were 1.61 (1.38 to
1.88) for all cause mortality, 1.14 (0.84 to 1.56) for incident
myocardial infarction, 1.44 (1.16 to 1.79) for vascular mortality,
and 1.84 (1.48 to 2.29) for non-vascular mortality (fig 2).
Self controlled case series analysis
Among the main cohort of 2 471 patients, 444 who had an
incident myocardial infarction during follow-up had been
exposed to a proton pump inhibitor at some point concurrently
with clopidogrel and aspirin (table 7⇓). Comparisons within
individuals adjusted for age gave an incident rate ratio of 0.75
(0.55 to 1.01). The result was similar when exposure was
restricted to strong 2C19 inhibiting proton pump inhibitors only
(table 7⇓). For the secondary exposures of interest, the incident
rate ratio for myocardial infarction was 0.57 (0.31 to 1.06) for
ranitidine, 1.65 (0.87 to 3.15) for paroxetine/fluoxetine, and
0.84 (0.49 to 1.45) for citalopram (fig 2). There was limited
evidence of a slight increase in the risk of myocardial infarction
in the two week period before exposures of interest began
(incident rate ratio 1.39 (0.71 to 2.70) for periods before
exposure to proton pump inhibitors), although this failed to
reach significance (table 7⇓). A sensitivity analysis categorising
this period as baseline gave similar results to those presented.
Model checking and sensitivity analyses
There was limited evidence that the proportional hazards
assumption might not have been valid for the association
between proton pump inhibitor exposure andmortality outcomes
(Wald test, P=0.05). The hazard ratios obtained across stratified
age groups, however, were not substantially different from the
overall hazard ratio presented. The results of the cohort study
were unchanged when we performed a complete case analysis.
For the self controlled case series, the sensitivity analyses to
check the assumptions underpinning the method did not differ
materially from the main analysis, indicating the assumptions
were likely to be valid.
Discussion
Using a traditional cohort analysis we observed an increased
risk of myocardial infarction or all cause mortality among
clopidogrel and aspirin users exposed to a proton pump inhibitor,
with a hazard ratio of 1.37 (1.27 to 1.48). We also saw a similar
increased risk for the individual outcomes of all cause mortality,
incident myocardial infarction, and vascular mortality.
Comparable results were seen when we looked at non-vascular
mortality and drug exposures other than proton pump inhibitors,
including drugs that would not be expected to interact with
clopidogrel (such as ranitidine and citalopram). These observed
associations with exposures and outcomes that would not be
expected from the theoretical drug interaction suggest these
results could be driven by important differences between proton
pump inhibitor users and non-users rather than showing a causal
association. When we used a within person study design to
remove the influence of differences between people we found
no association between proton pump inhibitor exposure and
myocardial infarction, with a rate ratio of 0.75 (0.55 to 1.01) in
a self controlled case series.
We believe the association found in the cohort analysis is
unlikely to be causal for several reasons. Firstly, the mechanism
behind a possible causal association involves a pharmacokinetic
drug interaction between clopidogrel and proton pump inhibitors
at the CYP450 2C19 enzyme. This interaction would reduce
the effectiveness of clopidogrel’s antiplatelet activity and would
be expected to lead specifically to an increased risk of vascular
events in proton pump inhibitor users compared with non-users.
While our results show such an increase in risk, the effect is not
specific to vascular events, as shown by the hazard ratio for
non-vascular mortality of 1.61 (1.42 to 1.82). One explanation
for this strong and unpredicted finding could be unmeasured
confounding, whereby people receiving proton pump inhibitors
are at an increased risk for harmful outcomes, independent of
proton pump inhibitor use. The baseline characteristics of users
and non-users suggest that users are older and have more
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comorbidities than non-users, which would support this
hypothesis. Although we adjusted for several confounding
factors, it is likely that unadjusted confounding remains, whether
from illnesses we have not been able to measure, through
systematic differences in the severity of underlying diseases,
which wewere unable to determine or incomplete ascertainment
of the known confounders.
Secondly, the results of secondary analyses examining the
effects of other long term drug use are revealing. The results
for other strong CYP450 2C19 inhibitors such as
paroxetine/fluoxetine mirror those seen for proton pump
inhibitors, which is consistent with an interaction at the 2C19
enzyme. The similar results seen for ranitidine and citalopram,
however, would not be predicted from the pharmacokinetics of
these drugs. An alternative and plausible explanation is that
people who are prescribed long term drug treatment in addition
to clopidogrel are inherently at higher risk of harmful outcomes
but not through a causal association with the treatments they
receive. Intuitively, this makes sense as “illness” is itself a risk
factor for adverse outcomes and is clearly also associated with
an increased chance of receiving drugs. Such confounding can
be difficult to overcome in non-randomised studies of drug use.
The results of the self controlled case series analysis also suggest
that the cohort results could be explained by confounding
between people. The self controlled case series design removes
all fixed confounding between individuals as the comparisons
are made within an individual, relying on patients who have
both exposed and unexposed periods for the main comparison
of interest. These results provide no evidence of an increased
risk of incident myocardial infarction during periods when
patients are exposed to proton pump inhibitors (incident rate
ratio 0.75 (0.55 to 1.01) for proton pump inhibitor, 0.57 (0.31
to 1.06) for ranitidine, or 0.84 (0.49 to 1.45) for citalopram).
The near protective effect seen with proton pump inhibitors and
ranitidine is difficult to explain; it could represent higher
adherence to aspirin and clopidogrel during periods of
co-prescribing with these drugs, though this is not testable in
the present study. Although the incident rate ratio for
paroxetine/fluoxetine was raised (1.65), this estimate was based
on a relatively small number of events and the 95% confidence
interval of 0.87 to 3.15 suggests it could well be a chance
finding.
Taken together, a plausible explanation for our results is that
the increased risk of both vascular and non-vascular harmful
outcomes seen in patients receiving proton pump inhibitors and
other long term drugs could be caused by confounding between
people. Although accounting for such confounding can be
difficult, the use of approaches such as the self controlled case
series, which is less prone to differences between people, can
solve this problem. The lack of association seen between proton
pump inhibitor use andmyocardial infarction with this approach
argues against a clinically relevant interaction between
clopidogrel and proton pump inhibitors.
Strengths and limitations of study
The main advantages of this study are the large sample size
taken from a well validated population based data source and
the use of newly established data linkages allowing accurate
ascertainment of incident myocardial infarction cases and
recorded causes of death.
Some limitations could arise from the possibility of imperfect
recording of exposures and outcomes. TheMyocardial Ischaemia
National Audit Project does not record data for patients who
die before they reach hospital, and so these cases are
systematically missing in our ascertainment of incident
myocardial infarction. It is unlikely that underascertainment
would happen differently for proton pump inhibitor users and
non-users and would therefore be expected to bias any result
towards the null. It is also unlikely that this would have any
impact on the primary outcome, as all cause mortality includes
patients who die before arriving at hospital.
Exposure status was probably incorrectly assigned to some
extent as it was determined from prescribing records and we
cannot know whether patients obtained all drugs from the
pharmacist or took them as directed. For our analysis we had
to make an assumption about likely exposure status for all drugs
during apparent gaps in prescribing records. We chose to
consider gaps of less than 180 days to indicate continued
treatment, allowing for possible stockpiling or obtaining drugs
from alternative sources. We also repeated analyses when the
continuous treatment period was assumed to be shorter (60 or
90 days), and these alternative assumptions had no substantial
effect on the results presented here.
Comparison with other studies
These results need to be viewed in the context of other studies
examining this drug interaction. Our overall findings are
consistent with several studies that also failed to find an
association between proton pump inhibitors and less favourable
outcomes in clopidogrel users.2 6-12 Of note, the case control
study by Valkhoff et al12 did find a harmful association but when
comparisons were restricted to former or current users of proton
pump inhibitors the association was not found, again suggesting
a biased result driven by confounding between people. The only
randomised trial designed to specifically answer this question
was unfortunately stopped early and so is underpowered and
unable to rule out a clinically relevant effect.11 The available
results, however, did not point towards any harmful association.
Of note, the 2C19 enzyme is subject to genotypic variation,
with some people having naturally poor 2C19metabolic activity.
It might be expected that poor metabolisers would experience
reduced benefit from taking clopidogrel if the 2C19 pathway is
critical for the metabolism of clopidogrel to its active form. A
recent meta-analysis, however, found that 2C19 genotype does
not influence clopidogrel effectiveness.24 This finding questions
the critical role of the 2C19 pathway for clopidogrel
effectiveness; it is possible that other pathways compensate in
patients with compromised 2C19 activity.
The findings from our cohort analysis are also consistent with
several studies showing an association between proton pump
inhibitor use and vascular harm,1 3-5 but we believe we have
shown why this association is unlikely to be causal. In extreme
cases the magnitude of harm observed by others was greater
than the maximum likely protective effect of clopidogrel,4 5
again suggesting an alternative explanation is needed for the
results. Nonetheless, some studies have preferentially identified
a harmful effect of strong CYP450 2C19 inhibitors but not weak
inhibitors, a finding that is not readily explained.1 Because of
prescribing patterns in the UK, more than 90% of proton pump
inhibitor use is accounted for by lansoprazole, omeprazole, and
esomeprazole, all of which are strong inhibitors. When we
restricted our exposure to only these proton pump inhibitors,
the results were similar.
Conclusions and policy implications
In conclusion, these results suggest that the drug interaction
between proton pump inhibitors and clopidogrel does not result
in clinical harm. The observed associations between proton
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pump inhibitor use and several harmful outcomes are likely to
be non-causal and could be explained by differences between
people. An analysis within individuals, which removes the effect
of differences between people, found no association between
proton pump inhibitor use and myocardial infarction. Current
guidelines from the American College of Cardiology
Foundation/American Heart Association recognise the
conflicting nature of previous studies of this question and
recommend re-evaluation of the need for proton pump inhibitor
use in this setting.25 The use of a proton pump inhibitor with
clopidogrel and aspirin is well proved to prevent harm through
gastrointestinal bleeding, and we should continue to consider
proton pump inhibitors as important prophylactic drugs in
patients at high risk.
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What is already known on this topic
Over recent years there has been a debate over whether the pharmacokinetic drug interaction between clopidogrel and proton pump
inhibitors reduces the antiplatelet effects of clopidogrel and leads to an increased risk of vascular events
Studies aiming to answer this question have had conflicting findings
What this study adds
The combination of a proton pump inhibitor with clopidogrel is associated with an increased risk of both vascular and non-vascular
adverse outcomes, but that this association is unlikely to be causal
The association is probably because of important differences between proton pump inhibitor users and non-users as a comparison
within individuals, which removes the effect of differences between people, found no association between the use of a proton pump
inhibitor and the risk of myocardial infarction
Tables
Table 1| Baseline characteristics by exposure classified according to proton pump inhibitor (PPI) status at first clopidogrel prescription
P value
Clopidogrel and aspirin
PPI (n=9111)No PPI (n=15 360)
<0.0017168Median age (years)
<0.0015323 (58)10 007 (65)Men
BMI (kg/m2):
0.005429 (5)480 (3)<20
2339 (26)3987 (26)20-25
5809 (64)10 004 (65)>25
534 (6)889 (6)Missing
Smoking:
0.0052780 (31)4781 (31)Non-smoker
1503 (16)2760 (18)Current
4799 (53)7777 (51)Ex-smoker
29 (0.3)42 (0.3)Missing
Alcohol:
<0.0011080 (12)1528 (10)Non-drinker
687 (8)938 (6)Ex-drinker
254 (3)399 (3)Amount not specified
1908 (21)3060 (20)<2 units/day
4106 (45)7488 (49)3-6 units/day
606 (7)1180 (8)>6 units/day
470 (5)767 (5)Status unknown
History of:
<0.0013090 (34)4404 (29)Diabetes
0.0011095 (12)1629 (11)Peripheral vascular disease
0.27292 (80)12 198 (79)Coronary heart disease
0.5954 (10)1571 (10)Ischaemic stroke
<0.0011381 (15)2038 (13)Cancer
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Table 2| Association between exposure to proton pump inhibitor (PPI) and vascular/mortality outcomes in patients taking clopidogrel and
aspirin
Hazard ratio (95% CI)No of events (all cause mortality or
incident myocardial infarction)Median follow-up (days)No of peopleExposure* Fully adjusted†Crude
Primary outcome
All cause mortality or incident myocardial infarction:
——134135516 680No PPI
1.37 (1.27 to 1.48)1.41 (1.31 to 1.52)141930112 345PPI
Secondary outcomes
All cause mortality:
——105836116 900No PPI
1.40 (1.29 to 1.52)1.44 (1.32 to 1.56)117031212 439PPI
Incident myocardial infarction:
——36935516 680No PPI
1.30 (1.12 to 1.50)1.38 (1.19 to 1.59)36530112 345PPI
Vascular mortality:
——61436116 900No PPI
1.25 (1.12 to 1.40)1.29 (1.15 to 1.44)61231212 439PPI
Non-vascular mortality:
——44436116 900No PPI
1.61 (1.42 to 1.82)1.64 (1.44 to 1.85)55831212 439PPI
*Captures whether patients were ever counted in this exposure group during follow-up.
†Adjusted for age, sex, BMI, smoking, alcohol, diabetes, peripheral vascular disease, coronary heart disease, ischaemic stroke, cancer.w
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Table 3| Association between exposure to strong CYP450 2C19 inhibiting proton pump inhibitor* and vascular/mortality in patients taking
clopidogrel and aspirin
Hazard ratio (95% CI)No of events (all cause mortality or
incident myocardial infarction)Median follow-up (days)No of patientsExposure† Fully adjusted‡Crude
Primary outcome
All cause mortality or incident myocardial infarction:
——141435917 405No strong PPI
1.39 (1.29 to 1.50)1.43 (1.33 to 1.54)134629211 910Strong PPI
Secondary outcomes
All cause mortality:
——111636717 425No strong PPI
1.43 (1.31 to 1.56)1.45 (1.34 to 1.58)111229912 012Strong PPI
Incident myocardial infarction:
——39135917 405No strong PPI
1.29 (1.12 to 1.49)1.37 (1.20 to 1.60)34329211 910Strong PPI
Vascular mortality:
——65536717 425No strong PPI
1.28 (1.15 to 1.44)1.27 (1.13 to 1.42)57129912 012Strong PPIs
Non-vascular mortality:
——46136717 425No strong PPI
1.71 (1.51 to 1.94)1.72 (1.52 to 1.95)54129912 012Strong PPI
*Omeprazole, esomeprazole, lansoprazole.
†Captures whether patients were ever counted in this exposure group during follow-up.
‡Adjusted for age, sex, BMI, smoking, alcohol, diabetes, peripheral vascular disease, coronary heart disease, ischaemic stroke, cancer.
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Table 4| Association between ranitidine exposure and vascular/mortality outcomes in patients taking clopidogrel and aspirin
Hazard ratio (95% CI)No of events (all cause mortality or
incident myocardial infarction)Median follow-up(days)No of patientsExposure* Fully adjusted†Crude
Primary outcome
All cause mortality or incident myocardial infarction:
——265543023 996No ranitidine
1.20 (0.99 to 1.46)1.23 (1.01 to 1.50)1051881561Ranitidine
Secondary outcomes
All cause mortality:
——214044124 004No ranitidine
1.25 (1.01 to 1.55)1.28 (1.04 to 1.59)881891595Ranitidine
Incident myocardial infarction:
——70943023 996No ranitidine
1.07 (0.72 to 1.59)1.11 (0.74 to 1.65)251881561Ranitidine
Vascular mortality:
——118544124 004No ranitidine
1.06 (0.78 to 1.45)1.08 (0.79 to 1.47)411891595Ranitidine
Non-vascular mortality:
——95544124 004No ranitidine
1.49 (1.11 to 1.99)1.54 (1.15 to 2.07)471891595Ranitidine
*Captures whether patients were ever counted in this exposure group during follow-up.
†Adjusted for age, sex, BMI, smoking, alcohol, diabetes, peripheral vascular disease, coronary heart disease, ischaemic stroke, cancer.
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Table 5| Association between paroxetine/fluoxetine exposure and vascular/mortality outcomes in patients taking clopidogrel and aspirin
Hazard ratio (95% CI)No of events (all cause mortality
or incident myocardial infarction)Median follow-up (days)No of patientsExposure* Fully adjusted†Crude
Primary outcome
All cause mortality or incident myocardial infarction:
——265142924 004No paroxetine/fluoxetine
1.42 (1.17 to 1.72)1.54 (1.27 to 1.87)1092351143Paroxetine/fluoxetine
Secondary outcomes
All cause mortality:
——213744024 049No paroxetine/fluoxetine
1.49 (1.20 to 1.84)1.62 (1.32 to 2.00)912361155Paroxetine/fluoxetine
Incident myocardial infarction:
——71042924 004No paroxetine/fluoxetine
1.13 (0.75 to 1.69)1.20 (0.80 to 1.81)242351143Paroxetine/fluoxetine
Vascular mortality:
——118344024 049No paroxetine/fluoxetine
1.29 (0.95 to 1.75)1.38 (1.02 to 1.88)432361155Paroxetine/fluoxetine
Non-vascular mortality:
——95444024 049No paroxetine/fluoxetine
1.73 (1.29 to 2.31)1.93 (1.44 to 2.58)482361155Paroxetine/fluoxetine
*Captures whether patients were ever counted in this exposure group during follow-up.
†Adjusted for age, sex, BMI, smoking, alcohol, diabetes, peripheral vascular disease, coronary heart disease, ischaemic stroke, cancer.
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Table 6| Association between citalopram exposure and vascular/mortality outcomes in patients taking clopidogrel and aspirin
Hazard ratio (95% CI)No of events (all cause mortality or
incident myocardial infarction)Median follow-up (days)No of patientsExposure* Fully adjusted†Crude
Primary outcome
All cause mortality or incident myocardial infarction:
——255342123 888No citalopram
1.52 (1.32 to 1.76)1.63 (1.42 to 1.88)2072251930Citalopram
Secondary outcomes
All cause mortality:
——204943223 893No citalopram
1.61 (1.38 to 1.88)1.74 (1.49 to 2.02)1792291960Citalopram
Incident myocardial infarction:
——69042123 888No citalopram
1.14 (0.84 to 1.56)1.26 (0.93 to 1.71)442251930Citalopram
Vascular mortality:
——113743223 893No citalopram
1.44 (1.16 to 1.79)1.54 (1.24 to 1.92)892291960Citalopram
Non-vascular mortality:
——91243223 893No citalopram
1.84 (1.48 to 2.29)1.98 (1.59 to 2.46)902291960Citalopram
*Captures whether patients were ever counted in this exposure group during follow-up.
†Adjusted for age, sex, BMI, smoking, alcohol, diabetes, peripheral vascular disease, coronary heart disease, ischaemic stroke, cancer.
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Table 7| Self controlled case series analysis. Association between exposure to proton pump inhibitor (PPI), ranitidine, paroxetine/fluoxetine,
or citalopram and incident myocardial infarction (defined by MINAP (Myocardial Ischaemia National Audit Project))* in patients taking
clopidogrel and aspirin
Age adjusted IRR (95% CI)No of events‡Patient yearsNo of patients†Exposure
—375708430No PPI
0.75 (0.55 to 1.01)395719444PPI
1.39 (0.71 to 2.70)10820114 days before PPI
—398749478No strong PPI
0.77 (0.57 to 1.03)372677432Strong PPI
1.34 (0.69 to 2.59)10820814 days before strong PPI
—7431373641No ranitidine
0.57 (0.31 to 1.06)265276Ranitidine
1.10 (0.26 to 4.65)224814 days before ranitidine
—7351384603No paroxetine/fluoxetine
1.65 (0.87 to 3.15)314744Paroxetine/fluoxetine
1.35 (0.17 to 10.62)112614 days before paroxetine/fluoxetine
—7271343632No citalopram
0.84 (0.49 to 1.45)437879Citalopram
—025914 days before citalopram
IRR=incident rate ratio.
*Analysis includes patients not exposed to PPIs to improve age adjustments.
†Captures number of patients ever included in each exposure group.
‡Includes repeat events where observed during study period.
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Figures
Fig 1 Pictorial representation of study design; indicative single patient timeline
Fig 2 Association between proton pump inhibitors, ranitidine, paroxetine/fluoxetine, or citalopram and all outcomes in cohort
analysis and self controlled case series. Relative risk expressed as hazard ratio for cohort analysis and incidence rate ratio
for self controlled case series
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